{"nctId":"NCT01172535","briefTitle":"A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines","startDateStruct":{"date":"2010-11"},"conditions":["HIV"],"count":97,"armGroups":[{"label":"Lopinavir/ritonavir","type":"EXPERIMENTAL","interventionNames":["Drug: Lopinavir/ritonavir"]}],"interventions":[{"name":"Lopinavir/ritonavir","otherNames":["Kaletra","LPV/r"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Weight equal to or greater than 3 kg, but less than 25 kg, at the time of enrollment\n* Confirmed diagnosis of HIV-1 infection\n* Lopinavir/ritonavir (LPV/r)-treatment naïve and LPV/r-treatment eligible as defined by country-specific guidelines or the WHO pediatric treatment guidelines and confirmed by investigator\n* Willingness to take two nucleoside reverse transcriptase inhibitos (NRTIs), in accordance with appropriate national or international treatment guidelines\n* Demonstrated ability and willingness to swallow tablets for children larger than 10 kg. This can be assessed before inclusion (for example, a test trial with similar size solid tablet such as tic-tac).\n* Participants in the weight band between 10 and 16.9 kg that are unable to swallow tablets will receive liquid formulation\n* Parent or legal guardian able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Planned concurrent use of non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors, or an entry inhibitor\n* Planned concurrent protease inhibitor (PI) use, other than LPV/r\n* Prior treatment with LPV/r. Prior treatment with other PIs is allowed.\n* Results of certain laboratory tests indicating adverse events of Grade 3 or greater\n* Results of a lipase test indicating adverse event of Grade 2 or greater or clinical evidence of pancreatitis within 30 days prior to study entry\n* Tuberculosis co-treatment with rifampicin-containing regimen\n* Treatment with any enzyme-inducing antiepileptic drugs, such as henobarbital, phenytoin or carbamazepine\n* Clinical condition requiring the use of a prohibited medication (see protocol for more details)\n* Clinically unstable child requiring acute treatment for a serious opportunistic infection\n* Chemotherapy for active malignancy\n* Any clinically significant diseases (other than HIV-1 infection) or clinically significant findings during the screening medical history or physical examination that, in the investigator's opinion, would compromise participation in this study\n* Treatment with experimental drugs for any indication within 30 days prior to study entry\n* Known history of cardiac conduction abnormality and/or underlying structural heart disease, including congenital long QT","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Weeks","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Lopinovir/Ritonavir Area Under the Concentration-time Curve (AUC0-24)","description":"Area under the curve over 24 hours (AUC0-24), as determined by a non-compartmental analysis of 12-hour pharmacokinetic sampling for lopinavir/ritonavir","paramType":"GEOMETRIC_MEAN","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"196","spread":null}]}]}]},{"type":"PRIMARY","title":"Maximum Concentration of Lopinavir/Ritonavir (Cmax)","description":"Maximum concentration of lopinavir/ritonavir, as determined by analysis of 12-hour pharmacokinetic sampling","paramType":"GEOMETRIC_MEAN","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.25","spread":null}]}]}]},{"type":"PRIMARY","title":"Minimum Concentration of Lopinavir/Ritonavir (Cmin)","description":"Minimum concentration of lopinavir/ritonavir, as determined by analysis of 12-hour pharmacokinetic sampling","paramType":"GEOMETRIC_MEAN","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":null}]}]}]},{"type":"PRIMARY","title":"Clearance of Lopinavir/Ritonavir (CL/F)","description":"Clearance of lopinavir/ritonavir, as determined by analysis of 12-hour pharmacokinetic sampling","paramType":"GEOMETRIC_MEAN","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Participants With an AUC of Less Than 10% of Adults","description":"Proportion of participants with an AUC less that 10% of adults (AUC0-24 \\<104 mcg\\*hr/mL)","paramType":"NUMBER","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Adherence","description":"Adherence, defined as proportion of doses taken (note: proportion could be greater than 1.0 for reasons such as tablets having to be taken twice due to first one being spit out or imprecise measurement of liquid doses)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"0.99","spread":null},{"groupId":"OG002","value":"1.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Efficacy (HIV Viral Load)","description":"Having HIV viral load \\<400 copies/mL at the week 24 visit","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Efficacy (CD4%)","description":"Having CD4%≥25 at the week 24 visit.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing Adverse Events of Grade 3 or 4","description":"Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009, which is available on the RSC web site (http://rsc.tech-res.com/safetyandpharmacovigilance/). Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Participants Tolerating LPV/r","description":"Participants were considered to have tolerated medication if they did not stop treatment before the 24 week PK visit for any reason other than completing treatment or death not related to treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":97},"commonTop":["Blood sodium decreased","Blood bicarbonate decreased","Cough","Rhinorrhoea","Pyrexia"]}}}